Publication date: Available online 31 October 2015
Source:Vaccine
Author(s): Liping Jiang, Rongjun Fan, Shiyang Sun, Peihu Fan, Weiheng Su, Yan Zhou, Feng Gao, Fei Xu, Wei Kong, Chunlai Jiang
Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16), as the main agents causing hand, foot and mouth disease (HFMD), have become a serious public health concern in the Asia-Pacific region. Recently, various neutralizing B cell epitopes of EV71 were identified as targets for promising vaccine candidates. Structural studies of Picornaviridae indicated that potent immunodominant epitopes typically lie in the hypervariable loop of capsid surfaces. However, cross-neutralizing antibodies and cross-protection between EV71 and CVA16 have not been observed. Therefore, we speculated that divergent sequences of the two viruses are key epitopes for inducing protective neutralizing responses. In this study, we selected 10 divergent epitope candidates based on alignment of the EV71 and CVA16 P1 amino acid sequences using the Multalin interface page, and these epitopes are conserved among all subgenotypes of EV71. Simultaneously, by utilizing the norovirus P particle as a novel vaccine delivery carrier, we identified the 71-6 epitope (amino acid 176–190 of VP3) as a conformational neutralizing epitope against EV71 in an in vitro micro-neutralization assay as well as an in vivo protection assay in mice. Altogether, these results indicated that the incorporation of the 71-6 epitope into the norovirus P domain can provide a promising candidate for an effective synthetic peptide-based vaccine against EV71.
from #Medicine via ola Kala on Inoreader http://ift.tt/1Q2PAdB
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
►
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
- ► Φεβρουαρίου (793)
-
▼
2015
(2119)
- ► Δεκεμβρίου (940)
-
▼
Οκτωβρίου
(414)
-
▼
Οκτ 31
(22)
- Influenza vaccine effectiveness against hospitalis...
- A new EV71 VP3 epitope in norovirus P particle vec...
- Pros and cons of VP1-specific maternal IgG for the...
- Differences in efficiency, satisfaction and advers...
- Pertussis vaccination during pregnancy in Vietnam:...
- PneuMum: Impact from a randomised controlled trial...
- Translating Research to Practice for Children With...
- Testing anti-HIV activity of antiretroviral agents...
- Risk of congenital cytomegalovirus infection among...
- Susceptibility of HPV16 and 18 to high level disin...
- Increased expression and dysregulated association ...
- Human papillomavirus infection in male patients wi...
- Hydrolyzed fish proteins reduced activation of cas...
- Contaminant release history identification in 2-D ...
- Medicine,New Articles,October 31st,2015
- Synthesis and comparison of the biological activit...
- 1,2,3-Triazole pharmacophore-based benzofused nitr...
- Discovery of bis-ary urea derivatives as potent an...
- Synthesis of di- and tri-saccharide fragments of S...
- Investigation of the mechanisms of Angelica dahuri...
- Retrospective case-series of Paecilomyces lilacinu...
- Meningitis caused by Pasteurella multocida in a do...
-
▼
Οκτ 31
(22)
Αναζήτηση αυτού του ιστολογίου
Σάββατο 31 Οκτωβρίου 2015
A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
Alimentary Pharmacology &Therapeutics, EarlyView. https://ift.tt/2qECBIJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.